Ono-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-α

Anti-Cancer Drugs

Volumn 9, Issue 3, 1998, Pages 273-282

  Matsushita, Kazuhiro ^a,b   Kobayashi, Masanobu ^a   Totsuka, Yasunori ^b   Hosokawa, Masuo ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

CD4 T cell; Lipid A; Transplantation resistance; Tumor necrosis factor

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; LIPID A DERIVATIVE; MONOCLONAL ANTIBODY; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; SODIUM 2 DEOXY 2 [(9 PHENYLNONANOYLOXY)TETRADECANOYL]AMINO 3 O (9 PHENYLNONANOYL) DEXTRO GLUCOPYRANOSE 4 SULFATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL;

EID: 0031954473     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199803000-00010     Document Type: Article

References (45)

1. Satoh M, Inagawa H, Shimada Y, Soma G, Oshima H, Mizuno D. Endogenous production of tumor necrosis factor in normal mice and human cancer patients by interferons and other cytokines combined with biological response modifiers of bacterial origin. J Biol Response Mod 1987; 6: 512-24.
2. Yamazaki M, Okutomi T. Augmentation of cytotoxin from murine bone marrow and peritoneal macrophages by tumor transplantation. Cancer Res 1989; 49: 352-6.
3. Kusama T, Soga T, Shioya E, et al. Synthesis and antitumor activity of lipid A analogs having aphosphonooxyethyl group with alpha- or beta-configuration at position 1. Chem Pharm Bull 1990; 38: 3366-72.
4. Johnson AG, Tomai MA, Chen YF, Odean M. A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues. J Immunother 1991; 10: 398-4.
5. Nakatsuka M, Kumazawa Y, Matsuura M, Homma JY, Kiso M, Hasegawa A. Enhancement of nonspecific resistance to bacterial infections and tumor regression by treatment with synthetic lipid A-subunit analogs. Critical role of N-and 3-O-linked acyl groups in 4-O-phosphono-D-glucosamine derivatives. Int J Immunopharmacol 1989; 11: 349-58.
6. Nakatsuka M, Kumazawa Y, Homma JY, Kiso M, Hasegawa A. Inhibition in mice of experimantal metastasis of B16 melanoma by the synthetic lipid-A subunit analogue GLA-60. Int J Immunopharmacol 1991; 13: 11-9.
7. Sato K, Saiki I, Yoo YC, et al. DT-5461, a new synthetic lipid A analogue, inhibits lung and live metastasis of tumor in mice. Jpn J Cancer Res 1992; 83: 1081-7.
8. Shimizu T, Haketa Y, Iwamoto Y, et al. Relation between the biologic activities analogs in mice. Mol Biother 1992; 4: 184-7.
9. Shimizu T, Iwamoto Y, Yanagihara Y, Ikeda K, Achiwa K. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice. Int J Immunopharmacol 1992; 14: 1415-20.
10. Shimizu T, Ohtsuka Y, Yanagihara Y, Akamatsu S, Ikeda K, Achiwa K. Biological activity of chemically synthesized core sugar linked lipid A analog, heptose-(alpha 1-5)-2-keto-3-deoxyoctonic acid-(alpha 2-6)-2,3-diacyloxyacylglucosamine 4-phosphate. Int J Immunopharmacol 1992; 14: 221-6.
11. Matsumoto N, Aze Y, Akimoto A, Fujita T. Restoration of immune responses in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative. Immunopharmacology 1997; 36: 69-8.
12. Ueda H, Yamazaki M. Induction of tumor necrosis factor in a murine tumor by systemic administration of a novel synthetic lipid A analogue, ONO-4007. J Immunother 1997; 20: 65-9.
13. Morita S, Yamamoto M, Kamigaki T, Saitoh Y. Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages. Kobe J Med Sci 1996; 42: 219-31.
14. + alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996; 156: 2436-42.
15. Hattori Y, Szabo C, Gross S, Thiemermann C, Vane JR. Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Eur J Pharmacol 1995; 291: 83-90.
16. Satoh M, Matsumura T, Nakamoto M, Yamazaki M. Inhibition of TNF-triggering activity of lipopolysaccharide by a proteinaceous factor from normal mouse liver extract. J Immunol 1995; 155: 877-85.
17. Kobayashi M, Nagayasu H, Hamada J, Takeichi N, Hosokawa M. ONO-4007, a new synthetic lipid A derivative, induces differentiation of rat myelomonocytic leukemia cells in vitro and in vivo. Exp Hematol 1994; 22: 454-9.
18. Yang D, Satoh M, Ueda H, Tsukagoshi S, Yamazaki M. Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994; 38: 287-93.
19. Kuramitsu Y, Nishibe M, Ohiro Y, et al. A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-α in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anti-Cancer Drugs 1997; 8: 500-8.
20. Kuramitsu Y, Ohiro Y, Matsushita K, Obaba M, Kobayashi M, Hosakawa M. The mechanisms of locally enhanced production of tumor necrosis factor-α in tumor tissues by the administration of a new synthetic lipid A analog. ONO-4007, in hepatoma-bearing rats. Anti-Cancer Drugs 1997; 8: 886-93.
21. Kuramitsu Y, Matsushita K, Ohiro Y, Obara M, Kobayashi M, Hosokawa M. Therapeutic effects of a new synthetic lipid A analog, ONO-4007, on rat hepatoma KDH-8 depend on tumor necrosis factor-sensitivity of the tumor cells. Anti-Cancer Drugs 1997; 8: 898-901.
22. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986; 164: 777-93.
23. Freudenberg N, Joh K, Westphal O, Mittermayer C, Freudenberg MA, Galanos C. Haemorrhagic tumour necrosis following endotoxin administration. I. Communication: morphological investigation on endotoxin-induced necrosis of the methylcholanthrene (Meth A) tumour in the mouse. Virchou's Arch A Pathol Anat Histopathol 1984; 403: 377-89.
24. Conti P, Dempsey RA, Reale M, et al. Activation of human natural killer cells by lipopolysaccharide and generation of interleukin-1 alpha, beta, tumour necrosis factor and interleukin-6. Effect of IL-1 receptor antagonist. Immunology 1991; 73: 450-6.
25. Ogawa T, Uchida H, Amino K. Immunobiological activities of chemically defined lipid A from lipopolysaccharides of Porphyromonas gingivalis. Microbiology 1994; 140: 1209-16.
26. Akahane K, Someya K, Tsutomi Y, Akimoto T, Tohgo A. Antitumor synthetic lipid A analog DT-5461a upregulates cytokine expression in a murine macrophage cell line through LPS pathway. Cell Immunol 1994; 155: 42-52.
27. Paleolog EM, Katsikis P, Harris G, et al. Antilipid A monoclonal antibody HA-1A decreases the capacity of bacterial lipopolysaccharide to activate human vascular endothelial cells by an immune adherence mechanism. Cytokine 1993; 5: 570-7.
28. Pluznik DH, Mergenhagen SE. Synergistic action of lipopolysaccharide and tumor-promoting phorbol esters: two-signal requirement for colony-stimulating factor production by murine bone marrow cells. Exp Hematol 1986; 14: 1029-36.
29. Hultner L, Staber FG, Mergenthaler HG, Dormer P. Production of murine granulocyte-macrophage colony-stimulating factors (GM-CSF) by bone marrow derived and non-hemopoietic cells in vivo. Exp Hematol 1982; 10: 798-8.
30. Mergenthaler HG, Staber FG, Hultner L, Dormer P. The response of murine splenic granulocyte-macrophage colony-forming cells to lipid A in vivo. Exp Hematol 1982; 10: 637-49.
31. Winn H. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 1961; 86: 228-31.
32. Xu ZY, Hosokawa M, Morikawa K, Hatakeyama M, Kobayashi H. Overcoming suppression of antitumor immune reactivity in tumor-bearing rats by treatment with bleomycin. Cancer Res 1988; 48: 6658-63.
33. Midorikawa Y, Yamashita T, Sendo F. Modulation of the immune response to transplanted tumors in rats by selective depletion of neutrophils in vivo using a monoclonal antibody: abrogation of specific transplantation resistance to chemical carcinogen-induced syngeneic tumors by selective depletion of neutrophils in vivo. Cancer Res 1990; 50: 6243-7.
34. Yuan L, Kuramitsu Y, Li Y, Kobayashi M, Hosokawa M. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor beta by treatment with bleomycin. Cancer Immunol Immunother 1995; 41: 355-62.
35. Gorelik L, Bar-Dagan Y, Mokyr MB. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J Immunol 1996; 156: 4298.
36. Chang CH, Furue M, Tamaki K. B7-1 expression of Langerhans cells is up-regulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10. Eur J Immunol 1995; 25: 394-8.
37. Rival Y, Del Maschio A, Rabiet MJ, Dejana E, Duperray A. Inhibition of platelet endothelial cell adhesion molecule-1 synthesis and leukocyte transmigration in endothelial cells by the combined action of TNF-alpha and IFN-gamma. J Immunol 1996; 157: 1233-41.
38. Neumann B, Machleidt T, Lifka A, et al. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration. J Immunol 1996; 156: 1587-93.
39. + T cell infiltration. J Immunol 1992; 149: 2954-60.
40. Yuan L, Kobayashi M, Kuramitsu Y, Li Y-Q, Matsushita K, Hosokawa M. Enhancement of macrophage tumoricidal activity hy treatment of rats bearing KDH-8 hapatoma with bleomycin is related to inhibition of the tumor-derived transforming growth factor-β. Cancer Immunol Immunother 1998; in press.
41. + T lymphocyte clones. J Immunol 1997; 158: 5612-8.
42. Suda T, Okazaki T, Naito Y, et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-13.
43. Hahn S, Gehri R, Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 1995; 146: 57-79.
44. Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995; 86: 646-50.
45. Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181: 1615-21.